Details of the Drug
General Information of Drug (ID: DMQ0RXA)
| Drug Name |
11C-GSK-215083
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms | 11C-5-HT 6 receptor antagonist (neurodegenerative disease), GlaxoSmithKline; 11C-GSK-215083 PET maging agent (neurodegenerative disease), GlaxoSmithKline | ||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Structure | 3D Structure is Not Available |
![]() |
|||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Neurodegenerative disorder | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | 8A20-8A23 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References


